Enyo Pharma

French tech company | Builders Republic

About

Clinical-stage biotech developing oral drugs for kidney and liver disease — its lead candidate, an FXR agonist, is in Phase 2 trials for chronic kidney disease, the rare genetic disorder Alport syndrome, and the liver condition MASH, using a virus-inspired approach to modulate host-cell functions.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Series C
Founded
2014
City
LYON
Region
Auvergne-Rhône-Alpes
Legal name
ENYO PHARMA
SIREN
799831011
Tracked rounds
1
Amount raised
27 M€ raised since 2020

Funding rounds

  • Series C — 2024

Investors